Meditip
Meditip is a South Korea-based regulatory affairs consulting firm providing licensing, clinical development, and global market entry services for pharmaceutical, medical device, IVD, and health functional food companies across Korea, the US, Europe, Japan, and China.
- Company typePrivate
- Founded2007
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Meditip does
Meditip is a South Korea-based regulatory affairs (RA) consulting firm founded in 2007 that provides licensing and approval support for pharmaceuticals, biologics, medical devices, in vitro diagnostics (IVDs), health functional foods, and combination products across Korea, the United States, Europe, Japan, China, and Southeast Asia. The company's core service platform spans domestic and international regulatory approval consulting, insurance/reimbursement strategy, clinical development support, global market entry services, R&D commercialization, and CDMO (Contract Development and Manufacturing Organization) management consulting. Meditip also operates as a domestic representative for foreign companies seeking Korean market entry and, following the August 2024 acquisition of LSK SMO for 45 billion KRW, provides clinical trial site management organization (SMO) services.
Meditip generates revenue primarily through project-based and retainer-style professional services fees across five service lines: regulatory affairs consulting, clinical development, CDMO management, health functional food consulting, and SMO services. Since 2014, the company has completed more than 911 pharmaceutical and over 1,000 medical device regulatory projects, with reported revenue of 88 billion KRW in 2022 and management guidance of 150+ billion KRW for 2023. The company maintains an operating profit margin consistently above 15-20% annually. Go-to-market relies on direct B2B sales supported by a paid newsletter (75+ issues), annual symposiums drawing 200+ industry attendees, the Medtech School educational program for medical device startups, and integration within the DreamCIS/Tigermed ecosystem, which extends its effective reach to 62 countries.
Following the 2022 acquisition by DreamCIS (itself majority-owned by Chinese global CRO Tigermed), Meditip sits within an integrated drug development platform alongside DreamCIS (clinical) and LCS (non-clinical). The company raised 140 billion KRW in H2 2024 from Temasek, Highlight Capital, JL Partners, Sprouts International Holdings, and JC Asset Management, valuing it at 520 billion KRW post-money. Meditip is preparing for a KOSDAQ IPO targeted for H2 2026, which would make it the first publicly listed RA consulting company in Korea. Park Yang-soo was appointed CEO in April 2025, succeeding founder Yoo Jung-hee who transitioned to DreamCIS group-level strategy.
Meditip firmographics
Firmographics- Name
- Meditip
- Legal name
- 주식회사 메디팁
- Website
- https://meditip.co.kr
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Meditip is a South Korea-based regulatory affairs consulting firm providing licensing, clinical development, and global market entry services for pharmaceutical, medical device, IVD, and health functional food companies across Korea, the US, Europe, Japan, and China.
- Ownership category
- akta.pro rank
Meditip industry classification
Industry- Product category
- Healthcare Regulatory Affairs Consulting
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Meditip is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Meditip business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Regulatory Affairs (RA) Consulting Services: Meditip provides professional consulting services for regulatory approvals of pharmaceuticals, medical devices, IVDs, health functional foods, and cosmetics. Revenue is generated on a project-by-project basis, typically structured as one-time fees per engagement or retainer-based contracts for ongoing regulatory support.
- Clinical Development Consulting: Clinical protocol design, IND/NDA/BLA submission support, clinical trial operation management, vendor matching, and post-marketing surveillance services. Revenue streams are project-based consulting fees.
- CDMO Management Services: CMC and CDMO management consulting for biopharmaceutical development, including production strategy design, partner selection, and quality/regulatory compliance management. Revenue is project-based consulting or retainer arrangements.
- Health Functional Food Consulting: Functional ingredient development, individual recognition type approval, labeling/advertising review, product registration, and import consulting for health functional foods.
- SMO (Site Management Organization) Services: Following the acquisition of LSK SMO's business rights (45 billion KRW), Meditip operates an SMO providing clinical trial site management, CRC deployment, and on-site clinical trial support services. Revenue is generated through service fees per clinical trial.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | Custom project-based pricing for regulatory consulting engagements |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Meditip product offering
Product offeringCore offering
Meditip is a healthcare regulatory affairs (RA) and clinical development consulting firm that guides Korean and global biotech, pharmaceutical, and medical device companies through complex regulatory approval processes across Korea, USA, Europe, Japan, China, and Southeast Asia. The company provides licensing consulting for drugs, biologics, medical devices, IVDs, health functional foods, and combination products, along with clinical development, CMC/CDMO management, global market entry support, insurance/pricing strategy, and domestic representative services for foreign firms.
Product overview
Meditip is a comprehensive Healthcare regulatory approval and clinical development consulting company offering a full-cycle service platform. The company provides integrated regulatory consulting services across pharmaceuticals, medical devices, convergence products, and health functional foods. Core services include regulatory approval (인허가), insurance/pricing strategy, clinical development, global market research and entry, R&D support, and CDMO operation consulting. The company operates through partnerships with global regulatory bodies and has 29 overseas offices. Meditip is a subsidiary of DreamCIS (Tigermed group) and is preparing for IPO as the first RA consulting company in Korea to pursue listing.
Differentiator
Problem solved
Functional benefit
Products and services
- Pharmaceutical Regulatory Approval (인허가) Services
Quantifiable outcome
- Over 1,000 medical device projects and 911 regulatory approval projects completed since 2014
- +3 more outcomes
Companies that use Meditip
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles5 records
Meditip technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Meditip partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered minor and core.
- Global Medical Research Center (글로벌의학연구센터)minorMOU for joint cooperation in human application testing for health functional foods. Global Medical Research Center conducts clinical and non-clinical research including human application tests for functional ingredient approvals. Meditip leverages this partnership to provide comprehensive one-stop services for health functional food development.
- PromedicisminorMeditip acquired Promedicis through a merger and acquisition, expanding into the aesthetic/esthetic segment and strengthening its CRO capabilities.
- LCS (비엑스플랜트)coreNon-clinical consulting company within the DreamCIS group. Together with Meditip (RA) and DreamCIS (clinical), LCS completes the end-to-end drug development platform providing A-to-Z services from preclinical through commercialization.
- Accerise (Japan)minorJapanese SMO company participating in the Korea-China-Japan SMO cooperation workshop organized by DreamCIS and Meditip. Part of the broader Tigermed group's SMO network spanning Korea, Japan, and China.
- LSK SMOcoreMeditip acquired LSK SMO's entire business rights for 45 billion KRW in August 2024, enabling Meditip to enter the SMO (Site Management Organization) market. LSK SMO was established in 2016 as a subsidiary of LSK Global Pharma Service and was Korea's #1 SMO. This acquisition marks Meditip's entry into clinical trial site management services.
- Newrazin (뉴라진)minorPartnership for full-cycle development of treatments for hereditary muscular diseases. Meditip provides regulatory affairs and clinical development support for Newrazin's pipeline.
- Cosmaxpharma (코스맥스파마)minorMOU signed for mutual cooperation in pharmaceutical development, leveraging complementary capabilities in development and regulatory affairs.
- Dongun Anatech (동운아나텍)minorMOU for medical device clinical and regulatory affairs cooperation for Dongun Anatech's D-SaLife saliva-based blood glucose measurement device. Meditip and DreamCIS support global regulatory strategy and clinical development for the device targeting China and India markets first.
- Korean New Drug Development Research Association (신약개발연구조합)minorTrilateral business agreement between the Association, DreamCIS, Meditip, and BX Plant (CDRO) for full-cycle new drug development support services for member companies, including R&D, non-clinical, regulatory affairs, clinical trials, business development, and investment.
- DreamCIS (드림씨아이에스)coreMeditip is a subsidiary of DreamCIS (acquired in 2022), which in turn is majority-owned by Chinese global CRO Tigermed. Meditip provides regulatory affairs (RA) services while DreamCIS provides clinical trial services, creating an integrated end-to-end drug development platform. The two companies jointly organize industry symposiums, share global networks, and cross-refer clients.
- Tigermed (타이거메드)coreTigermed is the parent company of DreamCIS, making Meditip part of the Tigermed group ecosystem. Tigermed operates in 62 countries with 10,000+ employees globally. The partnership enables Meditip to leverage Tigermed's global clinical trial infrastructure, regulatory networks, and multi-country market access capabilities for Korean biotech clients seeking to enter international markets.
- TGG (USA)minorUS-based regulatory partner providing support for FDA regulatory approvals and US market entry services for Korean pharmaceutical and medical device products.
- Woodley BioReg Ltd (Europe)minorEuropean regulatory partner supporting EMA/CE regulatory approvals and European market entry for Korean healthcare products.
- CMIC (Japan)minorJapanese regulatory and CRO partner supporting PMDA approvals and Japanese market entry for Korean pharmaceutical and medical device companies.
- Beijing Regitrans (China)minorChinese regulatory partner supporting NMPA/CFDA approvals and Chinese market entry for Korean pharmaceutical and medical device companies.
Scale indicators9 records
Recent moves11 records
Expansion highlights6 records
Meditip competitors and assessment
Company assessmentDirect peers
- LSK Global Pharma Service: Korean clinical CRO that previously owned LSK SMO (acquired by Meditip for 45B KRW). Operates as a direct Korean CRO competitor across clinical development and has overlapping customer base in Korean biotech.
- Pharmaresearch: Korean CRO providing clinical trial services to biotech and pharmaceutical companies in Korea. Comparable Korean mid-market CRO serving similar pharmaceutical and medical device customer base.
- CMIC Holdings: Japan's largest CRO and Meditip's regulatory partner for PMDA approvals. Provides full-service clinical development, regulatory affairs, and CDMO services across Asia, making it the closest Asian geographic comparable.
- C&R Research: Korean CRO providing clinical trial services. Mentioned in Meditip executive Kim Seon-a's background, indicating overlapping talent pool and customer base in Korean clinical research.
Broad incumbents
- Tigermed: Chinese global CRO that owns DreamCIS (Meditip's parent). Operates in 62 countries with 10,000+ employees, offering clinical, regulatory, and bioanalytical services. Comparable global CRO serving similar biotech customers.
- IQVIA: Global CRO and life sciences services leader offering clinical, regulatory, and commercial services worldwide. Larger-scale incumbent operating in same regulatory consulting category as Meditip but as part of broader portfolio.
- WuXi AppTec: China-headquartered global CRO/CDMO offering drug discovery, clinical, and regulatory services. Asian-headquartered incumbent with comparable biotech customer base across China and Korea.
- Parexel International: Global CRO with strong regulatory affairs consulting capabilities across FDA, EMA, and APAC markets. Direct overlap with Meditip's regulatory consulting offering as part of broader clinical CRO portfolio.
- Syneos Health: Global biopharmaceutical services organization providing clinical development and regulatory consulting. Broader CRO with overlapping regulatory affairs service offerings to pharma and biotech.
- Charles River Laboratories: Global CRO providing preclinical, clinical, and manufacturing services to biopharma. Larger established player with comparable regulatory and development consulting offerings.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Meditip social profiles
Digital presenceMeditip financial estimates
Financial estimateRevenue estimate
Valuation estimate
Meditip leadership team
Management profileNumber of profiles
Profiles5 records
Meditip subsidiaries and ownership
Company hierarchySubsidiaries1 record
Meditip funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Meditip M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Meditip
What does Meditip do?
Meditip is a healthcare regulatory affairs (RA) and clinical development consulting firm that guides Korean and global biotech, pharmaceutical, and medical device companies through complex regulatory approval processes across Korea, USA, Europe, Japan, China, and Southeast Asia. The company provides licensing consulting for drugs, biologics, medical devices, IVDs, health functional foods, and combination products, along with clinical development, CMC/CDMO management, global market entry support, insurance/pricing strategy, and domestic representative services for foreign firms.
Is Meditip a public or private company?
Meditip is a private company. It is classified as corporate owned and is currently operating.
When was Meditip founded?
Meditip was founded in 2007. It employs 11 to 50 people.
Where is Meditip based?
Meditip is headquartered in Seoul, South Korea, in the Asia region.
How does Meditip make money?
Five revenue lines are on record. Regulatory Affairs (RA) Consulting Services are the primary driver. The others are clinical Development Consulting, CDMO Management Services, health Functional Food Consulting and SMO (Site Management Organization) Services.
Who are Meditip's main competitors?
Direct peers on record are LSK Global Pharma Service, Pharmaresearch, CMIC Holdings and C&R Research. Broad incumbents are Tigermed, IQVIA, WuXi AppTec, Parexel International, Syneos Health and Charles River Laboratories.
Does Meditip have an API?
No public API is recorded for Meditip.
What industry is Meditip in?
Meditip's product category is Healthcare Regulatory Affairs Consulting. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 5417 and its SIC code is 8000.